Aptar Pharma buys Pulmotree after two-year partnership, but can Kolibri unlock inhaled biologics?
Aptar Pharma acquires Pulmotree to advance Kolibri inhaler technology for complex medicines. Commercial success depends on validation and adoption.
Pharma & Biotech
Pharma & Biotech
Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?
Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?
Pharma & Biotech
AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver?
AimedBio's BI 4060107 enters Phase 1 testing under a potential $991 million Boehringer Ingelheim deal. Safety and early activity remain unproven.
Pharma & Biotech
SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease
Serapha Bio's SERP-01 gene editing restores protective protein levels in four AATD patients. Explore the early results and Phase 2/3 plans.
Pharma & Biotech
ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027
Oruka Therapeutics' ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis testing. Explore the results and Phase 3 plans.
Pharma & Biotech
Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance?
Frontier's FMC-376 achieved a 56% response rate in 18 evaluable lung cancer patients, including prior KRAS inhibitor users. Can larger trials confirm benefit?
Pharma & Biotech
BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
BeOne reports new liver and lung cancer responses across three Phase 1 drugs, but dosing, safety and confirmatory evidence will shape development.
Pharma & Biotech
CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
CatalYm's visugromab lifted bladder cancer complete responses to 33% versus 8% with nivolumab alone. Can larger trials establish lasting benefit?
Pharma & Biotech
Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance?
Genmab and Incyte will test petosemtamab with a KRAS G12D inhibitor in metastatic colorectal cancer. Can dual pathway targeting overcome resistance?
Pharma & Biotech
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.